2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1132

The Musculoskeletal Master Educator Training Program: A New Resource and Professional Development Opportunity for Leaders in Medical Education
Abstract Number: 1825

the Non-Coding Genome and the Genetics of Systemic Lupus
Abstract Number: 815

The Novel Anti-BICD2 Autoantibody Potentially Predicts a Favorable Disease Course in SSc
Abstract Number: 2916

The Number of Micro-Haemorrhages and Micro-Thrombosis Detected By Nailfold Videocapillaroscopy Is a Good Predictor of Disease Activity in Systemic Sclerosis: The Validation Study of NEMO Score
Abstract Number: 3098

The Occurrence of Peripheral Arthritis Mutilans in Psoriatic Arthritis Is Associated with Certain Major Histocompatibility Class I Alleles
Abstract Number: 2243

The Paucity of the Evidence Base for American College of Rheumatology Practice Guidelines
Abstract Number: 2536

The Performance of a Single Centre Interventional Clinic in Early Rheumatoid Arthritis
Abstract Number: 2395

The Performance of the Kobayashi and Egami Scores in Detecting IVIG Resistance in Kawasaki Disease in a Single Centre Canadian Cohort Treated with IVIG and Low Dose Aspirin
Abstract Number: 3129

The Pharmacokinetics of Oxypurinol in Patients Treated with Hemodialysis and Allopurinol
Abstract Number: 900

The Phenotype of Macrophages in the Inflamed Vascular Wall of Giant Cell Arteritis Resembles the Phenotype of Non-Classical Monocytes
Abstract Number: 2310

The Predictive Risk Factors for Complication of Infection during the Treatment for Inflammatory Myopathies Complicated with Interstitial Lung Disease
Abstract Number: 1069

The Predictive Value of Acl and Anti-β2GPI in Patients with Acute Deep Vein Thrombosis
Abstract Number: 2766

The Predictive Value of Patient’s and Evaluator’s Global Assessment and Tender and Swollen Joint Count Differences on Treatment Efficacy in Psoriatic Arthritis: Data from a Longitudinal Multicenter Study
Abstract Number: 2793

The Predictors of Sustained Complete Remission in Lupus Nephritis
Abstract Number: 1701

The Presence of Depression Might be an Important Determinant of Achieving Minimal Disease Activity State in Psoriatic Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].